ZEPP vs. ALGS, MLSS, BLRX, DRIO, ICCM, RVPH, AMIX, RPHM, EQ, and BOLT Should you be buying Zepp Health stock or one of its competitors? The main competitors of Zepp Health include Aligos Therapeutics (ALGS), Milestone Scientific (MLSS), BioLineRx (BLRX), DarioHealth (DRIO), IceCure Medical (ICCM), Reviva Pharmaceuticals (RVPH), Autonomix Medical (AMIX), Reneo Pharmaceuticals (RPHM), Equillium (EQ), and Bolt Biotherapeutics (BOLT). These companies are all part of the "medical" sector.
Aligos Therapeutics (NASDAQ:ALGS ) and Zepp Health (NYSE:ZEPP ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk.
Aligos Therapeutics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, Zepp Health has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
Zepp Health has higher revenue and earnings than Aligos Therapeutics. Zepp Health is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.
60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 52.6% of Zepp Health shares are held by institutional investors. 16.5% of Aligos Therapeutics shares are held by insiders. Comparatively, 36.0% of Zepp Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Zepp Health had 5 more articles in the media than Aligos Therapeutics. MarketBeat recorded 7 mentions for Zepp Health and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.54 beat Zepp Health's score of 0.24 indicating that Zepp Health is being referred to more favorably in the news media.
Zepp Health has a consensus price target of $4.96, suggesting a potential upside of 457.24%. Given Aligos Therapeutics' higher probable upside, analysts plainly believe Zepp Health is more favorable than Aligos Therapeutics.
Zepp Health has a net margin of -8.66% compared to Zepp Health's net margin of -783.72%. Aligos Therapeutics' return on equity of -8.55% beat Zepp Health's return on equity.
Aligos Therapeutics received 21 more outperform votes than Zepp Health when rated by MarketBeat users. Likewise, 62.16% of users gave Aligos Therapeutics an outperform vote while only 40.00% of users gave Zepp Health an outperform vote.
Summary Zepp Health beats Aligos Therapeutics on 11 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ZEPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Zepp Health Competitors List
Related Companies and Tools
